Brentuximab vedotin

Generic Name: Brentuximab vedotin

Brand Names: Adcetris

Drug Type: Biotech

Chemical Formula: -

CAS Number: 914088-09-8

Unique Ingredient Identifier: 7XL5ISS668

Background: Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug labe...

Indication: Brentuximab vedotin is indicated in adult patients for the treatment of previously untreated stage III or IV classical Hodgkin's lymphoma (cHL) in combination with doxorubicin, vinblastine, and dacarbazine. It is also indicated for the treatment of cHL post-autologous hematopoietic stem cell transplantation (auto-HSCT) in patients at high risk of relapse or ...

Associated Conditions: CD30-expressing Mycosis Fungoides (MF), Classical Hodgkin's Lymphoma, Peripheral T-Cell Lymphoma (PTCL), Primary Cutaneous Anaplastic Large Cell Lymphoma, Systemic Anaplastic Large Cell Lymphoma, Stage 3 Classical Hodgkin's Lymphoma

Associated Therapies: -

Clinical Trials

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Phase 2

Active, not recruiting

Conditions: Enteropathy Associated T-cell Lymphoma
NK T-cell Lymphoma
T-cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Hepato-splenic T-cell Lymphoma
Adult T-cell Leukemia/Lymphoma

Interventions: Drug: Brentuximab vedotin

First Posted Date: 2015-10-28

Last Posted Date: 2024-09-30

Lead Sponsor: Deepa Jagadeesh

Target Recruit Count: 23

Registration Number: NCT02588651

Locations: 🇺🇸
Wayne State University, Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

and more 1 locations

An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

Phase 1

Completed

Conditions: Non-Hodgkin's Disease

Interventions: Biological: Nivolumab
Drug: Brentuximab Vedotin

First Posted Date: 2015-10-21

Last Posted Date: 2023-03-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 145

Registration Number: NCT02581631

Locations: 🇺🇸
Winship Cancer Institute., Atlanta, Georgia, United States
🇺🇸
University Of Chicago, Chicago, Illinois, United States
🇺🇸
Local Institution - 0003, New York, New York, United States

and more 24 locations

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

Phase 1

Completed

Conditions: Hodgkin Lymphoma

Interventions: Drug: brentuximab vedotin
Drug: nivolumab

First Posted Date: 2015-10-08

Last Posted Date: 2022-11-08

Lead Sponsor: Seagen Inc.

Target Recruit Count: 93

Registration Number: NCT02572167

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 10 locations

A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity

Phase 2

Completed

Conditions: Hodgkin Disease

Interventions: Drug: Brentuximab Vedotin

First Posted Date: 2015-10-05

Last Posted Date: 2018-05-11

Lead Sponsor: University of Birmingham

Target Recruit Count: 38

Registration Number: NCT02567851

Locations: 🇬🇧
University Hospital, Leicester, United Kingdom
🇬🇧
University Hospital of Wales, Cardiff, United Kingdom
🇬🇧
Norfolk and Norwich Hospital, Norwich, United Kingdom

and more 9 locations

Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus

Phase 2

Terminated

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Brentuximab vedotin
Drug: Placebo

First Posted Date: 2015-08-27

Last Posted Date: 2018-06-11

Lead Sponsor: Seagen Inc.

Target Recruit Count: 20

Registration Number: NCT02533570

Locations: 🇺🇸
Clayton Medical Associates, P.C., Saint Louis, Missouri, United States
🇺🇸
TriWest Research Associates, LLC, El Cajon, California, United States
🇺🇸
Lakes Research, LLC, Miami Lakes, Florida, United States

and more 14 locations

Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma

Phase 2

Completed

Conditions: Hodgkin Lymphoma

Interventions: Drug: Brentuximab Vedotin
Drug: Adriamycin
Drug: Dacarbazine

First Posted Date: 2015-07-22

Last Posted Date: 2020-08-24

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 34

Registration Number: NCT02505269

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting

Phase 2

Terminated

Conditions: Lymphatic Diseases

Interventions: Drug: Brentuximab Vedotin
Drug: Bendamustine

First Posted Date: 2015-07-16

Last Posted Date: 2021-05-27

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Target Recruit Count: 43

Registration Number: NCT02499627

Locations: 🇮🇹
Spedali Civili, Brescia, BS, Italy
🇮🇹
AOU Città della Salute e della Scienza, Torino, TO, Italy
🇮🇹
IRCCS Fondazione Pascale, Napoli, Italy

and more 2 locations

Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients

Phase 2

Completed

Conditions: Lymphatic Diseases

Interventions: Drug: Brentuximab Vedotin

First Posted Date: 2015-07-14

Last Posted Date: 2022-03-22

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Target Recruit Count: 25

Registration Number: NCT02497131

Locations: 🇮🇹
Ematologia e Trapianto IRCCS, Istituto Nazionale dei Tumori, Milano, Italy
🇮🇹
SC Ematologia - Città della Salute e della Scienza, Torino, Italy
🇮🇹
A.O. Universitaria S. Maria Della Misericordia Di Udine, Udine, Italy

and more 1 locations

Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL

Phase 1

Terminated

Conditions: ALK+ Anaplastic Large Cell Lymphoma

Interventions: Drug: Brentuximab vedotin
Drug: Imatinib

First Posted Date: 2015-06-04

Last Posted Date: 2022-03-03

Lead Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie

Target Recruit Count: 3

Registration Number: NCT02462538

Locations: 🇦🇹
Universitätsklinik f. Innere Medizin I, AKH Wien, Klinische Abteilung für Hämatologie und Hämostaseologie, Wien, Austria

A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL

Phase 2

Completed

Conditions: Primary Mediastinal Large B Cell Lymphoma

Interventions: Drug: Brentuximab Vedotin

First Posted Date: 2015-04-22

Last Posted Date: 2017-06-26

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Target Recruit Count: 15

Registration Number: NCT02423291

Locations: 🇮🇹
Divisione di Ematologia Azienda Ospedaliera "Bianchi Melacrino Morelli", Reggio Calabria, RC, Italy
🇮🇹
Unità funzionale di Ematologia A.O.U. Careggi, Firenze, FI, Italy
🇮🇹
Dip. Oncologia, Ematologia e Patologie dell'apparato respiratorio A.O.U. Policlinico di Modena, Modena, MO, Italy

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy